SAN DIEGO, Jan. 23, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands a… […]
New Drug Laws, Higher Rates of Legal Marijuana and CBD Use Underscore Importance of Staying Up to Date
SAN DIEGO, Jan. 22, 2020 /PRNewswire/ — Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, today announced th… […]
– Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409- 93% of patients showed liver fat reduction of at least 30% from baseline
SAN DIEGO, Jan. 22, 2020 /PRNewswire/ — Metacrine, Inc., a clinical-sta… […]
– Broadens Development of DB102 Beyond Oncology and PAH- Monetizes DB102 Prior to ENGINE Data Read-out
SAN DIEGO, Jan. 21, 2020 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today anno… […]
SAN DIEGO, Jan. 21, 2020 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, today announced that a… […]
Conference Call and Webcast Scheduled for Tuesday, February 4
SAN DIEGO, Jan. 20, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq… […]
– APD418 currently in Phase 1 clinical investigation – data expected this year
SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track des… […]
— Exclusive license option grants Bloom rights to intellectual property for genetic manipulation and extensive strain library of Akkermansia bacteria —
SAN DIEGO, Jan. 15, 2020 /PRNewswire/ — Bloom Science, a biopharmaceutical company focused on … […]
SAN DIEGO, Jan. 14, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of its common stock at a public offering price of $97.50 per s… […]
Biocept’s patented Target Selector(TM) technology enables new specimen type–cerebrospinal fluid (CSF)–to identify biomarkers that can aid physicians in making treatment decisions
SAN DIEGO, Jan. 14, 2020 /PRNewswire/ — Biocept, Inc. (NASDAQ: B… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
